SHANTHA BIOTECHNICS

Shantha Biotechnics Ltd was founded by Dr KI Varaprasad, an electronics engineer by profession, in 1993. Realising the need for an affordable Hepatitis-B vaccine for India, he decided to develop the technology in-house rather than importing it at a higher cost.

The project began modestly as a research and development (R&D) outfit at the Osmania University under the industry–university interactive programme in 1993 and later at the Centre for Cellular and Molecular Biology (CCMB), until an independent R&D facility was built.

In 1997, Shantha developed and commercialised India's first r-DNA Hepatitis-B vaccine. In July 2001, Shanvac -b was prequalified by World Health Organisation (WHO) and has since been supplied to UN agencies such as UNICEF and PAHO.

Merieux Alliance group, based in France, acquired majority stake in Shantha Biotechnics Limited (Shantha) in November, 2006. In July, 2009, the company was acquired by Sanofi, which is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions.

Today, Shantha is a fully integrated biotechnology company involved in R&D, manufacturing and marketing.

All material, information, data, images or content on this website is subject to copyright or other applicable intellectual property laws and no part of it can be reproduced in any form (including paper or electronic form) without prior written consent and approval from IBEF. Infringements are subject to prosecution under the applicable laws. For consent related queries and conditions, please write to info.brandindia@ibef.org